Daily aspirin reduces risk of ovarian cancer, regardless of genetics

Published Date: 08 Mar 2023

New findings show that frequent aspirin use provides protection against ovarian cancer, regardless of a person's genetic risk.

Read Full News

Latest News

Workplace Bending May Triple Miscarriage Risk

Frequently bending forward ≥ 30° in an occupation was associated with an increased risk of miscarriage.

Nitrous Oxide Cuts Pain in Office Hysteroscopy

Inhaled nitrous oxide significantly reduces pain during office hysteroscopy compared with ambient air.

Free Contraception Coverage Curbs Patients’ Costs in BC

Universal contraceptive coverage reduces out-of-pocket costs substantially in British Columbia, especially for young people.

Upcoming Billing Change Could Make Pregnancy Pricier

Under new billing codes starting in January, maternity care doctors will charge à la carte for visits and services related to pregnancy, childbirth, and postpartum care.

Interest in Alternative Menopause Treatments Surging

As menopause has become more visible online, experts see both benefits and risks, from greater patient engagement to the spread of misinformation.

J&J Beats Lawsuit Alleging That Talc Caused Three Women's Cancer

A Los Angeles jury on Friday sided with ⁠Johnson & Johnson in a lawsuit by the families of three women who alleged ⁠that the company's talc products caused ovarian...

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Latest News

Frequently bending forward ≥ 30° in an occupation was associated with an increased risk of miscarriage.

Inhaled nitrous oxide significantly reduces pain during office hysteroscopy compared with ambient air.

Universal contraceptive coverage reduces out-of-pocket costs substantially in British Columbia, especially for young people.

Under new billing codes starting in January, maternity care doctors will charge à la carte for visits and services related to pregnancy, childbirth, and postpartum care.

As menopause has become more visible online, experts see both benefits and risks, from greater patient engagement to the spread of misinformation.

A Los Angeles jury on Friday sided with ⁠Johnson & Johnson in a lawsuit by the families of three women who alleged ⁠that the company's talc products caused ovarian...

News All Time

Maternal Endometriosis Tied to Birth Defects

Endometriosis in mothers is associated with an increased risk for congenital anomalies in their infants.

Unpacking Emerging Evidence and Addressing Complex Questions in HER2+ Early Breast Cancer Office Hours

Unpacking Emerging Evidence and Addressing Complex Questions in HER2+ Early Breast Cancer Office Hours

Emerging Evidence and Expert Perspectives: Evolving Treatment Strategies in HER2+ Early Breast Cancer

Emerging Evidence and Expert Perspectives: Evolving Treatment Strategies in HER2+ Early Breast Cancer

Scaling Excellence in HER2-Low and -Ultralow Breast Cancer: Real-World Strategies for Testing and Treatment Optimization

Scaling Excellence in HER2-Low and -Ultralow Breast Cancer: Real-World Strategies for Testing and Treatment Optimization

Facing Resistance: Novel Approaches for Endocrine-Resistant HR+/HER2- Breast Cancer

Facing Resistance: Novel Approaches for Endocrine-Resistant HR+/HER2- Breast Cancer

Beyond CLEOPATRA: Integrating Evolving Frontline Maintenance Strategies in HER2+ Metastatic Breast Cancer

Beyond CLEOPATRA: Integrating Evolving Frontline Maintenance Strategies in HER2+ Metastatic Breast Cancer

Powering Up First-Line Treatment in Triple-Negative Breast Cancer: How Antibody-Drug Conjugates and Immune Checkpoint Inhibitors Are Changing the Game

Powering Up First-Line Treatment in Triple-Negative Breast Cancer: How Antibody-Drug Conjugates and Immune Checkpoint Inhibitors Are Changing the Game

Platinum-Resistant Ovarian Cancer (PROC) Office Hours: Translating Clinical Trials Into Clinical Practice for PROC

Platinum-Resistant Ovarian Cancer (PROC) Office Hours: Translating Clinical Trials Into Clinical Practice for PROC

ACOG: American College of Obstetricians and Gynecologists

ASRM: American Society for Reproductive Medicine

SMFM: Society for Maternal-Fetal Medicine

SGO: Society of Gynecologic Oncology

TMS: The Menopause Society

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in GTN

Former UCLA Gynecologist Pleads Guilty to Sex Abuse After Conviction Was Overturned

The plea was unexpected

HHS Changing Its Tune on Contraceptive Access

Focus of Title X program shifting to "natural family planning" and encouragement of pregnancy

Recommended News For You

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Recommended Articles For You

Evolution of Cancer Care Through Developmental Therapeutics 

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options 

Lymphomatoid Papulosis: What You Need to Know 

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.

2.

Including Bereavement in the Care Continuum.

3.

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

4.

enhancing survivors of brain tumors' quality of life.

5.

Food insecurity linked to tumor growth in pediatric neuroblastoma

1.

Revolutionizing Cancer Care with Fulphila: A New Hope for Patients

2.

Beyond the Battle: Navigating Life After Cancer

3.

Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options

4.

Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know

5.

A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Efficient Management of First line ALK-rearranged NSCLC - Part III

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Navigating the Complexities of Ph Negative ALL - Part XVI

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot